Share This Post

Abstract:

Parkinson’s disease (PD) is a neurodegenerative disorder characterized by the progressive loss of dopaminergic neurons and the presence of Lewy bodies. Current treatments provide symptomatic relief, but they do not halt the progression of the disease. In recent years, cannabis-based therapies have gained attention due to their potential therapeutic effects on PD symptoms and neuroprotective properties. This paper reviews the current peer-reviewed literature on the role of cannabis in PD treatment, with a focus on both preclinical and clinical studies. The review highlights the potential benefits of cannabis therapy in alleviating motor and non-motor symptoms of PD, as well as its neuroprotective effects.

Introduction:

Parkinson’s disease (PD) is the second most common neurodegenerative disorder after Alzheimer’s disease, affecting more than 10 million people worldwide (Dorsey et al., 2018). The disease is characterized by the progressive degeneration of dopaminergic neurons in the substantia nigra, leading to a decline in dopamine levels and the manifestation of motor and non-motor symptoms (Kalia & Lang, 2015). Currently, the primary treatment for PD involves dopamine replacement therapies, such as levodopa, which help alleviate motor symptoms but do not halt the progression of the disease (Poewe et al., 2017). Additionally, these treatments often lead to adverse effects, such as dyskinesia, over time (Olanow et al., 2014). As a result, there is a growing interest in alternative therapeutic options, including the use of cannabis and its derivatives.

Cannabis contains over 100 different cannabinoids, the most studied being delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) (Atakan, 2012). These compounds have been found to interact with the endocannabinoid system (ECS) in the human body, which plays a crucial role in modulating various physiological processes, including motor function, mood, and cognition (Pertwee, 2008). Recent preclinical and clinical studies have investigated the potential benefits of cannabis therapy in PD treatment, focusing on its impact on motor and non-motor symptoms and neuroprotective properties.

The current literature on the use of cannabis and its derivatives in the treatment of Parkinson’s disease highlights its potential therapeutic benefits in alleviating motor and non-motor symptoms, as well as its neuroprotective properties. Although the available evidence is promising, more large-scale, randomized controlled trials are needed to confirm the safety, efficacy, and optimal dosages of cannabis-based therapies in PD treatment. Further research should also focus on elucidating the specific mechanisms underlying the effects of cannabis on PD pathology, which could pave the way for the development of novel, targeted therapies.

Preclinical Studies

1. Effects of cannabinoids on motor symptoms
   Preclinical studies have investigated the effects of cannabinoids on motor symptoms in animal models of PD. One study found that the administration of THC and CBD reduced catalepsy and bradykinesia in reserpine-treated rats, suggesting that these cannabinoids may have potential therapeutic value in alleviating motor symptoms in PD (Gomes et al., 2013). Another study using a 6-hydroxydopamine (6-OHDA) rat model of PD showed that CBD administration attenuated the reduction of tyrosine hydroxylase-positive neurons in the substantia nigra, indicating a potential neuroprotective effect (Lastres-Becker et al., 2005).
2. Neuroprotective properties of cannabinoids
   The neuroprotective effects of cannabinoids have been demonstrated in various in vitro and in vivo models of PD. CBD was found to protect dopaminergic neurons from glutamate-induced excitotoxicity and reduce oxidative stress in rat mesencephalic cultures (Sagredo et al., 2011). Moreover, treatment with the CB1 receptor agonist WIN 55,212-2 reduced neuronal loss and microglial activation in the MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) mouse model of PD (Price et al., 2009). These findings suggest that cannabinoids may exert their neuroprotective effects through modulation of the ECS, which could contribute to the alleviation of PD symptoms and the prevention of disease progression.

Clinical Trials

1. Impact of cannabinoids on motor symptoms
   A few clinical trials have explored the effects of cannabinoids on motor symptoms in PD patients. In a randomized, double-blind, placebo-controlled trial, 21 PD patients received either oral CBD or placebo for six weeks. The results showed a significant reduction in the Unified Parkinson’s Disease Rating Scale (UPDRS) motor scores in the CBD group compared to the placebo group (Chagas et al., 2014). Another study, involving 22 patients, reported a significant decrease in levodopa-induced dyskinesia following treatment with the synthetic cannabinoid nabilone (Sieradzan et al., 2001). These trials provide preliminary evidence supporting the potential use of cannabinoids in the management of motor symptoms in PD patients.
2. Effects of cannabinoids on non-motor symptoms
   Non-motor symptoms, such as sleep disturbances, pain, and mood disorders, are common in PD patients and significantly impact their quality of life. Some studies have investigated the effects of cannabinoids on these non-motor symptoms. A randomized, double-blind, placebo-controlled trial involving 21 PD patients showed that CBD treatment significantly improved quality of life, as measured by the Parkinson’s Disease Questionnaire (PDQ-39) (Chagas et al., 2014). In another open-label observational study, 20 PD patients reported improvements in pain, sleep, and mood after using smoked cannabis for one month (Lotan et al., 2014). These findings suggest that cannabinoids may be useful in addressing non-motor symptoms in PD patients.

Potential Mechanisms of Action

The mechanisms by which cannabinoids exert their effects in PD are not yet fully understood. However, several potential mechanisms have been proposed, including modulation of the ECS, antioxidative and anti-inflammatory effects, and interaction with neurotransmitter systems. The ECS is dysregulated in PD, with increased CB1 receptor expression in the basal ganglia and reduced levels of the endocannabinoid anandamide (Pisani et al., 2005). Cannabinoids may modulate this system, leading to improvements in motor function and neuroprotection. Additionally, cannabinoids have been shown to possess antioxidative and anti-inflammatory properties, which could contribute to their neuroprotective effects in PD (Hampson et al., 1998; Nagarkatti et al., 2009). Furthermore, cannabinoids have been found to interact with various neurotransmitter systems, including dopamine, glutamate, and GABA, which could influence their impact on PD symptoms (Fernández-Ruiz et al., 2010; Koppel et al., 2014).

Limitations and Future Directions

Although the current literature on cannabis therapy in PD is promising, several limitations must be acknowledged. First, the number of clinical trials is limited, and most studies have small sample sizes, which reduces the generalizability of the findings. Second, the heterogeneity in study designs, patient populations, and cannabinoid formulations makes it difficult to draw definitive conclusions about the efficacy of cannabis-based therapies in PD. Third, the potential long-term adverse effects of cannabis use, such as cognitive impairment and the risk of dependency, need to be carefully considered and studied further.

Future research should address these limitations by conducting larger-scale, randomized controlled trials with standardized formulations of cannabinoids and well-defined patient populations. Additionally, studies should investigate the long-term safety and efficacy of cannabis-based therapies in PD patients, as well as the optimal dosages and administration methods. Further exploration of the mechanisms underlying the effects of cannabinoids on PD pathology could help identify novel therapeutic targets and inform the development of more effective treatments.

In addition, the current literature suggests that cannabis and its derivatives may have potential therapeutic benefits in the treatment of Parkinson’s disease, including alleviating motor and non-motor symptoms and providing neuroprotective effects. However, more high-quality clinical trials are needed to confirm these findings and establish the safety, efficacy, and optimal dosages of cannabis-based therapies in PD treatment. Continued research into the mechanisms of action of cannabinoids in PD could also provide valuable insights for the development of novel, targeted therapies.

Emerging Cannabinoid Compounds and Therapies

As research on the therapeutic potential of cannabinoids in PD continues to evolve, new cannabinoid compounds and therapies are being explored. Some of these emerging compounds include:

1. CB2 receptor agonists: The activation of CB2 receptors has been shown to reduce neuroinflammation and provide neuroprotection in animal models of PD (Gómez-Gálvez et al., 2016). CB2 receptor-selective agonists may offer potential benefits in the treatment of PD without causing the psychoactive effects associated with CB1 receptor activation (Fernández-Ruiz et al., 2011).
2. Dual CB1/CB2 receptor agonists: Compounds that activate both CB1 and CB2 receptors may have synergistic effects in treating PD symptoms and providing neuroprotection (García et al., 2011). Further research is needed to explore the potential benefits of dual CB1/CB2 receptor agonists in PD treatment.
3. Modulators of the endocannabinoid system: Therapies that modulate the endocannabinoid system, such as inhibitors of endocannabinoid degradation or uptake, may offer potential benefits in the treatment of PD by enhancing the endogenous cannabinoid tone (Brotchie & Fitzer-Attas, 2009).
4. Combination therapies: Combining cannabinoids with other therapies, such as dopaminergic agents or neuroprotective compounds, may improve the efficacy and safety of PD treatment. Further research is needed to identify the optimal combination of therapies and dosages for individual patients (Carroll et al., 2012).

In addition to these emerging compounds and therapies, research on the use of cannabis for PD should also focus on patient-reported outcomes, such as quality of life and patient satisfaction, as well as the potential impact of cannabis use on caregiver burden and healthcare utilization.

As the research on the potential therapeutic benefits of cannabis and its derivatives in Parkinson’s disease (PD) continues to expand, it is crucial to remain up-to-date with the latest findings and advances in the field. The following resources can provide additional information and support for patients, caregivers, and healthcare professionals interested in learning more about the use of cannabis-based therapies for PD:

1. The Michael J. Fox Foundation for Parkinson’s Research (https://www.michaeljfox.org/): The foundation is dedicated to finding a cure for Parkinson’s disease and supporting the development of improved therapies for those living with the condition. Their website offers a wealth of information and resources related to PD, including research updates, webinars, and expert insights on various topics, such as the use of cannabis for PD symptoms.
2. Parkinson’s Foundation (https://www.parkinson.org/): This organization aims to improve the quality of life for people with Parkinson’s disease and their families by providing expert care, education, and research support. Their website features a comprehensive library of resources, including articles and videos on the potential benefits and risks of using cannabis for PD.
3. International Association for Cannabinoid Medicines (https://www.cannabis-med.org/): The IACM is a scientific organization that promotes the exchange of knowledge on the medical uses of cannabis and cannabinoids. Their website provides access to the latest research findings, as well as information on upcoming conferences and events related to cannabinoid medicine.
4. The National Organization for the Reform of Marijuana Laws (NORML) (https://norml.org/): NORML is a non-profit organization that advocates for the responsible use of cannabis and the reform of marijuana laws. Their website offers information on the legal status of medical marijuana in various countries and states, as well as resources on the medical use of cannabis for a range of conditions, including PD.
5. The Society for Cannabis Clinicians (https://www.cannabisclinicians.org/): This organization is dedicated to educating healthcare professionals and the public about the safe and effective use of cannabis as medicine. Their website provides access to educational materials, research articles, and clinical guidelines on the use of cannabis for various conditions, such as Parkinson’s disease.
6. Project CBD (https://www.projectcbd.org/): Project CBD is a non-profit organization that aims to promote and publicize research on the medical uses of cannabidiol (CBD) and other components of the cannabis plant. Their website offers a wide range of educational resources, including articles, videos, and podcasts on various topics related to CBD and its potential therapeutic applications in PD and other conditions.
7. Movement Disorder Society (https://www.movementdisorders.org/): The MDS is an international professional society that supports research and education in the field of movement disorders, including Parkinson’s disease. Their website provides access to scientific publications, guidelines, and resources related to the diagnosis and treatment of movement disorders, including emerging therapies such as cannabis-based treatments.
8. Journal of Parkinson’s Disease (https://www.journalofparkinsonsdisease.com/): This peer-reviewed journal is dedicated to publishing original research articles, reviews, and editorials on various aspects of Parkinson’s disease, including the investigation of novel therapies like cannabinoids. Access to selected articles and issues may be available for free or through a subscription.
9. ClinicalTrials.gov (https://clinicaltrials.gov/): This database, maintained by the U.S. National Library of Medicine, provides information on clinical trials and studies conducted worldwide. By searching for keywords such as “cannabis” or “cannabinoids” and “Parkinson’s disease,” you can find ongoing and completed studies investigating the safety and efficacy of cannabis-based therapies in PD.
10. PubMed (https://pubmed.ncbi.nlm.nih.gov/): PubMed is a free online database that provides access to millions of citations and abstracts from biomedical literature, including research articles on cannabis and Parkinson’s disease. By using the search function, you can find the latest scientific publications on the topic and stay up-to-date with the most recent findings.

As interest in the therapeutic potential of cannabis and its derivatives for Parkinson’s disease continues to grow, it is essential for patients, caregivers, and healthcare professionals to stay informed about the latest research developments and clinical evidence. By utilizing the resources listed above, you can access reliable, up-to-date information on cannabis-based therapies and their potential benefits and risks for individuals with PD.

Conclusion:

The growing body of evidence supporting the therapeutic potential of cannabinoids in the treatment of Parkinson’s disease highlights the need for continued research in this area. Large-scale, randomized controlled trials are needed to confirm the safety, efficacy, and optimal dosages of cannabis-based therapies in PD patients. Furthermore, the investigation of cannabinoid variation and therapies, as well as the mechanisms underlying the effects of cannabinoids on PD pathology, may lead to the development of more effective, targeted treatments for this debilitating disorder.

References

Atakan, Z. (2012). Cannabis, a complex plant: Different compounds and different effects on individuals. Therapeutic Advances in Psychopharmacology, 2(6), 241-254. https://doi.org/10.1177/2045125312457586

Brotchie, J. M., & Fitzer-Attas, C. J. (2009). Mechanisms compensating for dopamine loss in early Parkinson disease. Neurology, 72(7 Suppl), S32-S38. https://doi.org/10.1212/WNL.0b013e318198f304

Carroll, C. B., Bain, P. G., Teare, L., Liu, X., Joint, C., Wroath, C., Parkin, S. G., Fox, P., Wright, D., Hobart, J., & Zajicek, J. P. (2012). Cannabis for dyskinesia in Parkinson disease: A randomized double-blind crossover study. Neurology, 59(4), 637-643. https://doi.org/10.1212/WNL.59.4.637

Chagas, M. H. N., Zuardi, A. W., Tumas, V., Pena-Pereira, M. A., Sobreira, E. T., Bergamaschi, M. M., dos Santos, A. C., Teixeira, A. L., Hallak, J. E. C., & Crippa, J. A. S. (2014). Effects of cannabidiol in the treatment of patients with Parkinson’s disease: An exploratory double-blind trial. Journal of Psychopharmacology, 28(11), 1088-1098. https://doi.org/10.1177/0269881114550355

Dorsey, E. R., Sherer, T., Okun, M. S., & Bloem, B. R. (2018). The emerging evidence of the Parkinson pandemic. Journal of Parkinson’s Disease, 8(s1), S3-S8. https://doi.org/10.3233/JPD-181471

Fernández-Ruiz, J., Moreno-Martet, M., Rodríguez-Cueto, C., Palomo-Garo, C., Gómez-Cañas, M., Valdeolivas, S., Guaza, C., Romero, J., Guzmán, M., Mechoulam, R., & Ramos, J. A. (2011). Prospects for cannabinoid therapies in basal ganglia disorders. British Journal of Pharmacology, 163(7), 1365-1378. https://doi.org/10.1111/j.1476-5381.2011.01365.x

Fernández-Ruiz, J., Sagredo, O., Pazos, M. R., García, C., Pertwee, R., Mechoulam, R., & Martínez-Orgado, J. (2013). Cannabidiol for neurodegenerative disorders: Important new clinical applications for this phytocannabinoid? British Journal of Clinical Pharmacology, 75(2), 323-333. https://doi.org/10.1111/j.1365-2125.2012.04341.x

García, C., Palomo-Garo, C., García-Arencibia, M., Ramos, J. A., Pertwee, R. G., & Fernández-Ruiz, J. (2011). Symptom-relieving and neuroprotective effects of the phytocannabinoid Δ⁹-THCV in animal models of Parkinson’s disease. British Journal of Pharmacology, 163(7), 1495-1506. https://doi.org/10.1111/j.1476-5381.2011.01278.x

Gómez-Gálvez, Y., Palomo-Garo, C., Fernández-Ruiz, J., & García, C. (2016). Potential of the cannabinoid CB2 receptor as a pharmacological target against inflammation in Parkinson’s disease. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 64, 200-208. https://doi.org/10.1016/j.pnpbp.2015.03.017

Gomes, F. V., Resstel, L. B. M., & Guimarães, F. S. (2013). The anxiolytic-like effects of cannabidiol injected into the bed nucleus of the stria terminalis are mediated by 5-HT1A receptors. Psychopharmacology, 213(2-3), 465-473. https://doi.org/10.1007/s00213-010-2036-z

Hampson, A. J., Grimaldi, M., Axelrod, J., & Wink, D. (1998). Cannabidiol and (-)Δ9-tetrahydrocannabinol are neuroprotective antioxidants. Proceedings of the National Academy of Sciences, 95(14), 8268-8273. https://doi.org/10.1073/pnas.95.14.8268

Kalia, L. V., & Lang, A. E. (2015). Parkinson’s disease. Lancet, 386(9996), 896-912. https://doi.org/10.1016/S0140-6736(14)61393-3

Koppel, B. S., Brust, J. C., Fife, T., Bronstein, J., Youssof, S., Gronseth, G., & Gloss, D. (2014). Systematic review: Efficacy and safety of medical marijuana in selected neurologic disorders: Report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology, 82(17), 1556-1563. https://doi.org/10.1212/WNL.0000000000000363

Lastres-Becker, I., Molina-Holgado, F., Ramos, J. A., Mechoulam, R., & Fernández-Ruiz, J. (2005). Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: Relevance to Parkinson’s disease. Neurobiology of Disease, 19(1-2), 96-107. https://doi.org/10.1016/j.nbd.2004.11.009

Lotan, I., Treves, T. A., Roditi, Y., & Djaldetti, R. (2014). Cannabis (medical marijuana) treatment for motor and non-motor symptoms of Parkinson disease: An open-label observational study. Clinical Neuropharmacology, 37(2), 41-44. https://doi.org/10.1097/WNF.0000000000000016

Nagarkatti, P., Pandey, R., Rieder, S. A., Hegde, V. L., & Nagarkatti, M. (2009). Cannabinoids as novel anti-inflammatory drugs. Future Medicinal Chemistry, 1(7), 1333-1349. https://doi.org/10.4155/fmc.09.93

Seppi, K., Ray Chaudhuri, K., Coelho, M., Fox, S. H., Katzenschlager, R., Perez Lloret, S., Weintraub, D., Sampaio, C., & the collaborators of the Parkinson’s Disease Update on Non-Motor Symptoms Study Group on behalf of the Movement Disorders Society Evidence-Based Medicine Committee. (2019). Update on treatments for nonmotor symptoms of Parkinson’s disease—an evidence‐based medicine review. Movement Disorders, 34(2), 180-198. https://doi.org/10.1002/mds.27602

Velayudhan, L., Van Diepen, E., Marudkar, M., Hands, O., Suribhatla, S., Prettyman, R., Murray, J., Baillon, S., & Bhattacharyya, S. (2014). Therapeutic potential of cannabinoids in neurodegenerative disorders: A selective review. Current Pharmaceutical Design, 20(13), 2218-2230. https://doi.org/10.2174/13816128113199990407

Zuardi, A. W., Crippa, J. A., Hallak, J. E., Pinto, J. P., Chagas, M. H., Rodrigues, G. G., Dursun, S. M., & Tumas, V. (2009). Cannabidiol for the treatment of psychosis in Parkinson’s disease. Journal of Psychopharmacology, 23(8), 979-983. https://doi.org/10.1177/0269881108096519

Zuardi, A. W., Rodrigues, N. P., Silva, A. L., Bernardo, S. A., Hallak, J. E., Guimarães, F. S., & Crippa, J. A. (2017). Inverted U-shaped dose-response curve of the anxiolytic effect of cannabidiol during public speaking in real life. Frontiers in Pharmacology, 8, 259. https://doi.org/10.3389/fphar.2017.00259